DOLPHMED (DOLPHMED) is currently trading at 6.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dolphin Medical Services Limited, founded in 1992, specializes in comprehensive diagnostic services, including radiology, pathology, and microbiology, primarily serving Andhra Pradesh's coastal regions. The company is debt-free and has been profitable for several years, demonstrating resilience in a competitive healthcare market. Dolphin Medical Services expanded its operations to include Dolphin Nethralaya, an eye care center offering advanced laser and research facilities. The company has diversified into IT, biotechnology, and herbal sectors, indicating strategic attempts at broadening its business scope.

Over the past 52 weeks, DOLPHMED has traded between a low of ₹5.90 and a high of ₹6.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

DOLPHMED has a market capitalization of approximately N/A. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

DOLPHMED’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of N/A Cr, DOLPHMED is classified as a N/A stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

DOLPHMED operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of DOLPHMED is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting is scheduled for September 21, 2026, and it is set to commence at 11:00 am.

Rarever Financial Advisors has fixed July 17, 2026 as the identified date for the open offer.